285 related articles for article (PubMed ID: 27197965)
1. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
Chen H; Liu X; Brendler CB; Ankerst DP; Leach RJ; Goodman PJ; Lucia MS; Tangen CM; Wang L; Hsu FC; Sun J; Kader AK; Isaacs WB; Helfand BT; Zheng SL; Thompson IM; Platz EA; Xu J
Prostate; 2016 Sep; 76(12):1120-9. PubMed ID: 27197965
[TBL] [Abstract][Full Text] [Related]
2. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.
Na R; Labbate C; Yu H; Shi Z; Fantus RJ; Wang CH; Andriole GL; Isaacs WB; Zheng SL; Helfand BT; Xu J
JAMA Netw Open; 2019 Dec; 2(12):e1918145. PubMed ID: 31880795
[TBL] [Abstract][Full Text] [Related]
3. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.
Shi Z; Platz EA; Wei J; Na R; Fantus RJ; Wang CH; Eggener SE; Hulick PJ; Duggan D; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Xu J
Eur Urol; 2021 Mar; 79(3):419-426. PubMed ID: 33257031
[TBL] [Abstract][Full Text] [Related]
4. Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases.
Na R; Ye D; Qi J; Liu F; Lin X; Helfand BT; Brendler CB; Conran C; Gong J; Wu Y; Gao X; Chen Y; Zheng SL; Mo Z; Ding Q; Sun Y; Xu J
Asian J Androl; 2016; 18(4):525-9. PubMed ID: 27140652
[TBL] [Abstract][Full Text] [Related]
5. A comparison of genetic risk score with family history for estimating prostate cancer risk.
Helfand BT
Asian J Androl; 2016; 18(4):515-9. PubMed ID: 27004541
[TBL] [Abstract][Full Text] [Related]
6. Clinical validity and utility of genetic risk scores in prostate cancer.
Helfand BT; Kearns J; Conran C; Xu J
Asian J Androl; 2016; 18(4):509-14. PubMed ID: 27297129
[TBL] [Abstract][Full Text] [Related]
7. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.
Kader AK; Sun J; Reck BH; Newcombe PJ; Kim ST; Hsu FC; D'Agostino RB; Tao S; Zhang Z; Turner AR; Platek GT; Spraggs CF; Whittaker JC; Lane BR; Isaacs WB; Meyers DA; Bleecker ER; Torti FM; Trent JM; McConnell JD; Zheng SL; Condreay LD; Rittmaster RS; Xu J
Eur Urol; 2012 Dec; 62(6):953-61. PubMed ID: 22652152
[TBL] [Abstract][Full Text] [Related]
8. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study.
Sandahl M; Pedersen BG; Ulhøi BP; Borre M; Sørensen KD
BJU Int; 2021 Dec; 128(6):702-712. PubMed ID: 33964113
[TBL] [Abstract][Full Text] [Related]
10. Association between family history of prostate cancer and positive biopsies in a Brazilian screening program.
Muller RL; Faria EF; Carvalhal GF; Reis RB; Mauad EC; Carvalho AL; Freedland SJ
World J Urol; 2013 Oct; 31(5):1273-8. PubMed ID: 22820620
[TBL] [Abstract][Full Text] [Related]
11. Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies.
Xu J; Resurreccion WK; Shi Z; Wei J; Wang CH; Zheng SL; Hulick PJ; Ross AE; Pavlovich CP; Helfand BT; Isaacs WB
Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):422-430. PubMed ID: 35347252
[TBL] [Abstract][Full Text] [Related]
12. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
[TBL] [Abstract][Full Text] [Related]
13. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M
BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304
[TBL] [Abstract][Full Text] [Related]
14. Exome-based genome-wide association study and risk assessment using genetic risk score to prostate cancer in the Korean population.
Oh JJ; Lee SJ; Hwang JY; Kim D; Lee SE; Hong SK; Ho JN; Yoon S; Sung J; Kim WJ; Byun SS
Oncotarget; 2017 Jul; 8(27):43934-43943. PubMed ID: 28380453
[TBL] [Abstract][Full Text] [Related]
15. Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.
Conran CA; Na R; Chen H; Jiang D; Lin X; Zheng SL; Brendler CB; Xu J
Asian J Androl; 2016; 18(4):520-4. PubMed ID: 27080480
[TBL] [Abstract][Full Text] [Related]
16. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.
Seibert TM; Fan CC; Wang Y; Zuber V; Karunamuni R; Parsons JK; Eeles RA; Easton DF; Kote-Jarai Z; Al Olama AA; Garcia SB; Muir K; Grönberg H; Wiklund F; Aly M; Schleutker J; Sipeky C; Tammela TL; Nordestgaard BG; Nielsen SF; Weischer M; Bisbjerg R; Røder MA; Iversen P; Key TJ; Travis RC; Neal DE; Donovan JL; Hamdy FC; Pharoah P; Pashayan N; Khaw KT; Maier C; Vogel W; Luedeke M; Herkommer K; Kibel AS; Cybulski C; Wokolorczyk D; Kluzniak W; Cannon-Albright L; Brenner H; Cuk K; Saum KU; Park JY; Sellers TA; Slavov C; Kaneva R; Mitev V; Batra J; Clements JA; Spurdle A; Teixeira MR; Paulo P; Maia S; Pandha H; Michael A; Kierzek A; Karow DS; Mills IG; Andreassen OA; Dale AM;
BMJ; 2018 Jan; 360():j5757. PubMed ID: 29321194
[TBL] [Abstract][Full Text] [Related]
17. Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.
Liss MA; Xu J; Chen H; Kader AK
Prostate; 2015 Sep; 75(12):1322-8. PubMed ID: 25982801
[TBL] [Abstract][Full Text] [Related]
18. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
Winchester DA; Till C; Goodman PJ; Tangen CM; Santella RM; Johnson-Pais TL; Leach RJ; Xu J; Zheng SL; Thompson IM; Lucia MS; Lippman SM; Parnes HL; Isaacs WB; De Marzo AM; Drake CG; Platz EA
Prostate; 2017 Jun; 77(8):908-919. PubMed ID: 28317149
[TBL] [Abstract][Full Text] [Related]
19. Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs.
Jiang H; Liu F; Wang Z; Na R; Zhang L; Wu Y; Zheng J; Lin X; Jiang D; Sun J; Zheng SL; Ding Q; Xu J
Prostate; 2013 Nov; 73(15):1651-9. PubMed ID: 23868750
[TBL] [Abstract][Full Text] [Related]
20. The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer.
Castro E; Mikropoulos C; Bancroft EK; Dadaev T; Goh C; Taylor N; Saunders E; Borley N; Keating D; Page EC; Saya S; Hazell S; Livni N; deSouza N; Neal D; Hamdy FC; Kumar P; Antoniou AC; Kote-Jarai Z; ; Eeles RA
Oncologist; 2016 Jun; 21(6):716-22. PubMed ID: 27151655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
